A systematic development approach (ICH Q8) that builds quality into the product by understanding the process and defining a design space, rather than testing quality in at the end. Anchored by critical quality attributes and critical process parameters.
QbD starts from the end and works backwards. You define the Quality Target Product Profile — what the product must be to be safe and effective in use — then derive the critical quality attributes that deliver it, then identify the material attributes and process parameters that drive those CQAs, and only then design a process and control strategy that holds them. Quality is designed in, not inspected in at the end.
Two ideas do most of the work. The design space is the multidimensional combination of inputs and parameters demonstrated to assure quality; movement within it is not considered a change requiring regulatory approval, which buys real operational flexibility. Process Analytical Technology supports that by measuring quality attributes in-line or at-line during manufacture rather than waiting for finished-product testing.
The trade is honest: QbD front-loads development effort — designed experiments, risk assessment, mechanistic understanding — in exchange for a more robust process, fewer deviations and investigations later, and greater post-approval flexibility. ICH Q12 extended that logic explicitly into lifecycle change management with established conditions and post-approval change management protocols.
- —Sequence: QTPP → CQAs → material attributes and CPPs → design space → control strategy.
- —Design space is demonstrated, not asserted — usually via designed experiments and risk assessment.
- —Movement within an approved design space is not a change requiring prior approval.
- —PAT enables real-time measurement in place of end-product testing alone.
- —Front-loads development effort to buy robustness and post-approval flexibility.
- —Extended by ICH Q12 (established conditions, post-approval change management protocols).
ICH Q8(R2) Pharmaceutical Development; ICH Q9(R1) Quality Risk Management; ICH Q10 Pharmaceutical Quality System; ICH Q11 (drug substance); ICH Q12 (lifecycle management); FDA guidance, PAT — A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance (2004).
Frequently asked questions
What does QbD stand for?
QbD stands for Quality by Design.
What is QbD?
A systematic development approach (ICH Q8) that builds quality into the product by understanding the process and defining a design space, rather than testing quality in at the end. Anchored by critical quality attributes and critical process parameters.
Which regulations cover QbD?
ICH Q8(R2) Pharmaceutical Development; ICH Q9(R1) Quality Risk Management; ICH Q10 Pharmaceutical Quality System; ICH Q11 (drug substance); ICH Q12 (lifecycle management); FDA guidance, PAT — A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance (2004).
SPEQ decodes published regulatory concepts in plain language. Definitions are a practitioner reference, not legal or regulatory advice.
Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.